Amphastar Pharma Files 8-K on Financial Condition
Ticker: AMPH · Form: 8-K · Filed: 2024-02-28T00:00:00.000Z
Sentiment: neutral
Topics: financial-condition, 8-K, pharmaceuticals
TL;DR
**Amphastar just dropped an 8-K on their financials, standard stuff, no major red flags.**
AI Summary
Amphastar Pharmaceuticals, Inc. filed an 8-K on February 28, 2024, to report on its results of operations and financial condition. The filing, under SEC File Number 001-36509, indicates that the company is based in Rancho Cucamonga, California, and operates in the pharmaceutical preparations industry. This report is a standard disclosure of financial information.
Why It Matters
This filing provides investors with updated information on Amphastar Pharmaceuticals' financial performance, which can influence investment decisions and market perception.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial results and does not indicate any unusual or high-risk events.
Key Players & Entities
- Amphastar Pharmaceuticals, Inc. (company) — Registrant
- February 28, 2024 (date) — Date of Report
- 001-36509 (other) — Commission File Number
- Rancho Cucamonga, California (other) — Company location
- 909-980-9484 (other) — Company phone number
FAQ
What is the purpose of this 8-K filing by Amphastar Pharmaceuticals, Inc.?
The 8-K filing by Amphastar Pharmaceuticals, Inc. is to report on the 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as of February 28, 2024.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported in this 8-K is February 28, 2024.
What is the Commission File Number for Amphastar Pharmaceuticals, Inc.?
The Commission File Number for Amphastar Pharmaceuticals, Inc. is 001-36509.
Where is Amphastar Pharmaceuticals, Inc.'s principal executive office located?
Amphastar Pharmaceuticals, Inc.'s principal executive office is located at 11570 6th Street, Rancho Cucamonga, California 91730.
What is the Standard Industrial Classification (SIC) for Amphastar Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) for Amphastar Pharmaceuticals, Inc. is 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-02-28 16:38:00
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share AMPH The NASDAQ Stock Mar
Filing Documents
- amph-20240228x8k.htm (8-K) — 43KB
- amph-20240228xex99d1.htm (EX-99.1) — 812KB
- 0001297184-24-000004.txt ( ) — 1011KB
- amph-20240228.xsd (EX-101.SCH) — 3KB
- amph-20240228_lab.xml (EX-101.LAB) — 15KB
- amph-20240228_pre.xml (EX-101.PRE) — 10KB
- amph-20240228x8k_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 28, 2024, Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press release, dated February 28, 2024, issued by Amphastar Pharmaceuticals, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 28, 2024 Amphastar Pharmaceuticals, Inc. By: /s/ WILLIAM J. PETERS William J. Peters Chief Financial Officer, Executive Vice President and Treasurer